Companies Avid Bioservices
Avid Bioservices (CDMO): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Avid Bioservices’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers36th pct.Of 14 peer CEOs
CEO pay, last three years
- $6,181,824FY2022
- $6,461,784FY2023
- $4,475,343FY2024
CEO total pay was $4,475,343 in fiscal 2024, down from $6,461,784 in fiscal 2023.
FY2024: salary $650,000 · bonus $0 · stock awards $3,776,336 · option awards $0
Executives and directors
Daniel Hart · CFORichard Richieri · COOMark Ziebell · General CounselMatthew Kwietniak · CCONicholas Green · CEOCatherine J. Mackey, Ph.D · Independent DirectorEsther M. Alegria, Ph.D · Independent DirectorGregory P. Sargen · Independent DirectorJeanne A. Thoma · Independent DirectorJoseph Carleone, Ph.D · Chair of the BoardRichard B. Hancock · Independent Director
Frequently asked questions
Who was the highest-paid executive at Avid Bioservices in fiscal 2024?
As disclosed, Nicholas Green (President and Chief Executive Officer) was the highest-paid executive at Avid Bioservices in fiscal 2024, with total compensation of $4,475,343.
How does Avid Bioservices's chief executive pay compare to its disclosed peer group?
As disclosed, Nicholas Green's total compensation ranked at the 36th percentile of Avid Bioservices's disclosed peer group.
What is Avid Bioservices's CEO-to-median employee pay ratio?
As disclosed, Avid Bioservices's CEO-to-median employee pay ratio was 35:1.
How much does Avid Bioservices spend in total on board compensation for fiscal 2024?
As disclosed, Avid Bioservices reported total board compensation of $1,491,110 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nicholas Green | $650,000 | $0 | $3,776,336 | $0 | $0 | $0 | $49,007 | $4,475,343 |
| President and Chief Executive Officer | ||||||||
| Daniel Hart | 445,000 | 0 | 944,075 | 0 | 0 | 0 | 52,157 | 1,441,232 |
| Chief Financial Officer | ||||||||
| Mark Ziebell | 425,000 | 0 | 557,001 | 0 | 0 | 0 | 52,157 | 1,034,158 |
| Vice President, General Counsel and Corporate Secretary | ||||||||
| Matthew Kwietniak | 362,000 | 0 | 566,439 | 0 | 0 | 0 | 47,433 | 975,872 |
| Chief Commercial Officer | ||||||||
| Richard Richieri | 375,000 | 0 | 472,027 | 0 | 0 | 0 | 36,907 | 883,934 |
| Chief Operations Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Nicholas Green | $4,475,343 | $6,461,784 | $6,181,824 | ↓ −1,986,441 |
| Daniel Hart | 1,441,232 | 1,936,898 | 2,067,208 | ↓ −495,666 |
| Mark Ziebell | 1,034,158 | 1,377,399 | 1,291,708 | ↓ −343,241 |
| Matthew Kwietniak | 975,872 | 1,283,884 | — | ↓ −308,012 |
| Richard Richieri | 883,934 | 1,109,387 | — | ↓ −225,453 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is to provide compensation that will attract, motivate, retain and reward high-performing talent in our industry and foster a pay-for-performance philosophy by tying a significant portion of pay to financial performance as well as other goals that support the creation of sustainable long-term stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Anderson Pay Advisors, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Matthew Kwietniak | RSU | 2023-07-09 | — | — | 20,346 | — | $283,216 |
| Mark Ziebell | RSU | 2023-07-09 | — | — | 20,007 | — | 278,497 |
| Daniel Hart | RSU | 2023-07-09 | — | — | 33,911 | — | 472,041 |
| Richard Richieri | RSU | 2023-07-09 | — | — | 16,955 | — | 236,014 |
| Nicholas Green | RSU | 2023-07-09 | — | — | 135,644 | — | 1,888,165 |
| Richard Richieri | PSU | 2023-07-09 | 8,478 | 16,955 | — | 33,911 | 236,013 |
| Mark Ziebell | PSU | 2023-07-09 | 10,004 | 20,008 | — | 40,015 | 278,504 |
| Matthew Kwietniak | PSU | 2023-07-09 | 10,173 | 20,347 | — | 40,693 | 283,223 |
| Nicholas Green | PSU | 2023-07-09 | 67,822 | 135,645 | — | 271,289 | 1,888,171 |
| Daniel Hart | PSU | 2023-07-09 | 16,956 | 33,911 | — | 67,822 | 472,034 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Matthew Kwietniak | $283,216 | $283,223 | $0 | 50.0% |
| Mark Ziebell | 278,497 | 278,504 | 0 | 50.0% |
| Daniel Hart | 472,041 | 472,034 | 0 | 50.0% |
| Richard Richieri | 236,014 | 236,013 | 0 | 50.0% |
| Nicholas Green | 1,888,165 | 1,888,171 | 0 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Richieri | RSU | 8,478 | — | $16,955 |
| Mark Ziebell | RSU | 10,004 | — | 20,008 |
| Matthew Kwietniak | RSU | 10,173 | — | 20,347 |
| Richard Richieri | PSU | 16,955 | — | 33,908 |
| Daniel Hart | RSU | 16,956 | — | 33,911 |
| Mark Ziebell | PSU | 20,007 | — | 40,014 |
| Matthew Kwietniak | PSU | 20,346 | — | 40,694 |
| Richard Richieri | PSU | 25,433 | — | 33,911 |
| Mark Ziebell | PSU | 30,011 | — | 40,015 |
| Matthew Kwietniak | PSU | 30,520 | — | 40,693 |
| Daniel Hart | PSU | 33,911 | — | 67,820 |
| Daniel Hart | PSU | 50,867 | — | 67,822 |
| Nicholas Green | RSU | 67,822 | — | 135,645 |
| Nicholas Green | PSU | 135,644 | — | 271,290 |
| Richard Richieri | RSU | 138,465 | — | 162,900 |
| Daniel Hart | RSU | 143,438 | — | 168,750 |
| Matthew Kwietniak | RSU | 162,563 | — | 191,250 |
| Nicholas Green | PSU | 203,467 | — | 271,289 |
| Nicholas Green | RSU | 208,038 | — | 244,750 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joseph Carleone, Ph.DIndependent · Board Chair · CDMO Business and Operations Leadership · Finance Capital Markets · Risk Oversight · Human Resources and Executive Compensation · Corporate Governance | $120,000 | $155,185 | $0 | — | — | $275,185 |
| Catherine J. Mackey, Ph.DIndependent · Risk Oversight · Human Resources and Executive Compensation · Corporate Governance | 90,000 | 155,185 | 0 | — | — | 245,185 |
| Gregory P. SargenIndependent · Audit (Chair) | 90,000 | 155,185 | 0 | — | — | 245,185 |
| Jeanne A. ThomaIndependent · CDMO Business and Operations Leadership · Risk Oversight · Human Resources and Executive Compensation · Corporate Governance | 90,000 | 155,185 | 0 | — | — | 245,185 |
| Esther M. Alegria, Ph.DIndependent · Audit | 85,000 | 155,185 | 0 | — | — | 240,185 |
| Richard B. HancockIndependent · Audit | 85,000 | 155,185 | 0 | — | — | 240,185 |
| Nicholas S. GreenEmployee director · CDMO Business and Operations Leadership · Finance Capital Markets | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $140,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 20,000 |
| Stock ownership guideline | $3 |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $560,000 |
| Equity awards (grant-date value) | $931,110 |
| All other compensation | $0 |
| Total cost of the board | $1,491,110 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Avid Bioservices as a peer
Companies that benchmark against CDMO
2 companies name CDMO as a compensation peer
- Anika Therapeutics, Inc.ANIKFY2025
- BIOLIFE SOLUTIONS INCBLFSFY2024
Each company listed discloses CDMO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CDMO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ANIP ANI Pharmaceuticals, Inc.CDNA CareDx, Inc.CDXS Codexis, Inc.CDAK Codiak BioSciences, Inc.SGMO Sangamo Therapeutics, Inc.RIGL Rigel Pharmaceuticals, Inc.TWST Twist Bioscience CorporationEBS Emergent BioSolutions Inc.LAB Standard BioTools Inc.CDXC ChromaDex CorporationLFCR Lifecore Biomedical, Inc.PACB Pacific Biosciences of California, Inc.QTRX Quanterix CorporationHBIO Harvard Bioscience, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Twist Bioscience Corporation | 2025 | Emily Leproust | $720,000 | $11,998,134 | $0 | $932,918 | $13,781,570 |
| 2 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 3 | Standard BioTools Inc. | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 4 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 5 | Emergent BioSolutions Inc. | 2025 | Joseph Papa | 1,037,385 | 1,638,500 | 1,191,500 | 1,446,640 | 5,321,147 |
| 6 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 7 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 8 | Avid Bioservices | 2024 | Nicholas Green | 650,000 | 3,776,336 | 0 | 0 | 4,475,343 |
| 9 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 10 | Codexis, Inc. | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
| 11 | Lifecore Biomedical, Inc. | 2025 | Paul Josephs | 550,000 | 274,996 | — | — | 1,115,305 |
| 12 | Harvard Bioscience, Inc. | 2025 | John Duke | 203,077 | 598,900 | 0 | 0 | 905,208 |
| — | Codiak BioSciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Sangamo Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | ChromaDex Corporation | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Avid Bioservices | 0% | RSU 50 · PSU 50 | No | Anderson Pay Advisors, LLC |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| CareDx, Inc. | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| ChromaDex Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| Codexis, Inc. | 95% | not disclosed | not disclosed | Pearl Meyer |
| Codiak BioSciences, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Emergent BioSolutions Inc. | 107% | Options 50 · PSU 50 | No | WTW |
| Harvard Bioscience, Inc. | not disclosed | RSU 50 · PRSU 50 | Yes — Relative Total Shareholder Return (TSR) | Frederic W. Cook & Co., Inc. |
| Lifecore Biomedical, Inc. | not disclosed | not disclosed | not disclosed | Frederic W. Cook & Co. |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Sangamo Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Standard BioTools Inc. | 160% | not disclosed | not disclosed | Pearl Meyer |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 35 : 1 |
|---|---|
| CEO total compensation | $4,475,343 |
| Median employee compensation | $126,552 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nicholas Stewart Green | Director | 2024-12-31 | A | 1,755 | $6 | $10,621 | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2024-12-31 | A | 1,303 | 6 | 7,886 | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2024-12-31 | A | 1,755 | 6 | 10,621 | Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2024-12-31 | A | 1,755 | 6 | 10,621 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-01-09 | — | 2,976 | — | — | 1 insider, 7 accrual rows | ||
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 2,995 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | A | 464 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | A | 5,507 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-10 | D | 2,283 | 12 | 28,241 | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-10 | D | 200 | 12 | 2,474 | Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-01-27 | D | 20,128 | 0 | 0 | Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 11,755 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 54,455 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 2,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 104,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 455,512 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 7,794 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 32,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 19,675 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 98,120 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Esther M. Alegria | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Esther M. Alegria | Director | 2025-02-05 | D | 37,746 | — | — | Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 19,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 159,375 | — | — | Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 102,730 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 19,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 124,191 | — | — | Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 113,878 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 2,938 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 30,635 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 50,796 | — | — | Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 4,817 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 1,430 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 107,137 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 59,212 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 8,785 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 49,535 | — | — | Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 36,368 | — | — | Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2025-02-05 | D | 45,611 | — | — | Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 17,679 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 55,310 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 14,286 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 66,799 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 1,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Esther M. Alegria | Director | 2025-02-05 | D | 8,376 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 130,324 | — | — | Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 308,486 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 11,623 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 112,735 | — | — | Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 1,733 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 19,675 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 19,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 48,498 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 77,454 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 881 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 58,018 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 108,579 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 51,413 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2025-02-05 | D | 19,403 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 92,461 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 71,120 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 54,760 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 7,014 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 34,271 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 56,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 21,429 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 19,675 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 43,379 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 86 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nicholas Stewart Green | Director | 2024-12-31 | A | 1,755 | $6 | $10,621 | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2024-12-31 | A | 1,303 | 6 | 7,886 | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2024-12-31 | A | 1,755 | 6 | 10,621 | Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2024-12-31 | A | 1,755 | 6 | 10,621 | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 2,995 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 1,060 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 946 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | A | 464 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 132 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 83 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 40 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | D | 506 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-09 | A | 5,507 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-10 | D | 2,283 | 12 | 28,241 | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-01-10 | D | 200 | 12 | 2,474 | Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-01-27 | D | 20,128 | 0 | 0 | Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 11,755 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 54,455 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 2,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 104,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 455,512 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 7,794 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 32,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 19,675 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 98,120 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Esther M. Alegria | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Esther M. Alegria | Director | 2025-02-05 | D | 37,746 | — | — | Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 19,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 159,375 | — | — | Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 102,730 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 19,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 124,191 | — | — | Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 113,878 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 2,938 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 30,635 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 50,796 | — | — | Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 4,817 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 1,430 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 107,137 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 59,212 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 8,785 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 49,535 | — | — | Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 36,368 | — | — | Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2025-02-05 | D | 45,611 | — | — | Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 17,679 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 55,310 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 14,286 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 66,799 | — | — | Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 1,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Esther M. Alegria | Director | 2025-02-05 | D | 8,376 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 130,324 | — | — | Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 308,486 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Stewart Green | Director | 2025-02-05 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 11,623 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 112,735 | — | — | Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 10,030 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 1,733 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 19,675 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory P. Sargen | Director | 2025-02-05 | D | 19,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 48,498 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 77,454 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 881 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kwietniak | Chief Commercial Officer | 2025-02-05 | D | 58,018 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 108,579 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 51,413 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2025-02-05 | D | 19,403 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 92,461 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 71,120 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hart | Chief Financial Officer | 2025-02-05 | D | 54,760 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 7,014 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard B. Hancock | Director | 2025-02-05 | D | 34,271 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Richieri | Chief Operations Officer | 2025-02-05 | D | 56,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Ziebell | V. P., General Counsel | 2025-02-05 | D | 21,429 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 8,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Carleone | Director | 2025-02-05 | D | 19,675 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine J. MacKey | Director | 2025-02-05 | D | 43,379 | — | — | Common | Form 4 ↗ |
Sources (124 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nicholas Green. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · page 36. As printed: 4,475,343. View filing ↗
- Section 01, Daniel Hart. DEF 14A, filed 2024-08-28. Section “Executive Compensation”. As printed: 1,441,232. View filing ↗
- Section 01, Mark Ziebell. DEF 14A, filed 2024-08-28. Section “Executive Compensation”. As printed: 1,034,158. View filing ↗
- Section 01, Matthew Kwietniak. DEF 14A, filed 2024-08-28. Section “Executive Compensation”. As printed: 975,872. View filing ↗
- Section 01, Richard Richieri. DEF 14A, filed 2024-08-28. Section “Executive Compensation”. As printed: 883,934. View filing ↗
- Section 03, Matthew Kwietniak RSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ziebell RSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Hart RSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Richieri RSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Nicholas Green RSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Richieri PSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ziebell PSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Kwietniak PSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Nicholas Green PSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Hart PSU. DEF 14A, filed 2024-08-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2024-08-28. Section “CEO Pay Ratio”. As printed: 35 : 1. View filing ↗
- Section 08, Joseph Carleone, Ph.D. DEF 14A, filed 2024-08-28. Section “Director Compensation”. As printed: 275,185. View filing ↗
- Section 08, Catherine J. Mackey, Ph.D. DEF 14A, filed 2024-08-28. Section “Director Compensation”. As printed: 245,185. View filing ↗
- Section 08, Gregory P. Sargen. DEF 14A, filed 2024-08-28. Section “Director Compensation”. As printed: 245,185. View filing ↗
- Section 08, Jeanne A. Thoma. DEF 14A, filed 2024-08-28. Section “Director Compensation”. As printed: 245,185. View filing ↗
- Section 08, Esther M. Alegria, Ph.D. DEF 14A, filed 2024-08-28. Section “Director Compensation”. As printed: 240,185. View filing ↗
- Section 08, Richard B. Hancock. DEF 14A, filed 2024-08-28. Section “Director Compensation”. As printed: 240,185. View filing ↗
- Section 08, Nicholas S. Green. DEF 14A, filed 2024-08-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Nicholas Stewart Green 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-09. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-10. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-01-10. Form 4, filed 2025-01-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-01-27. Form 4, filed 2025-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Stewart Green 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Stewart Green 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory P. Sargen 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory P. Sargen 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Carleone 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Stewart Green 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kwietniak 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine J. MacKey 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory P. Sargen 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Esther M. Alegria 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Esther M. Alegria 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Carleone 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Carleone 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Stewart Green 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kwietniak 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine J. MacKey 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory P. Sargen 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory P. Sargen 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanne A. Thoma 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanne A. Thoma 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Esther M. Alegria 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Carleone 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Stewart Green 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Stewart Green 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine J. MacKey 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine J. MacKey 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory P. Sargen 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kwietniak 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kwietniak 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kwietniak 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanne A. Thoma 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hart 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard B. Hancock 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Richieri 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ziebell 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Carleone 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Carleone 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine J. MacKey 2025-02-05. Form 4, filed 2025-02-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 560,000 + equity 931,110 + all other 0 = 1,491,110, summed across the director compensation table rows.
- Twist Bioscience Corporation, Section 10b CEO total. DEF 14A, filed 2026-01-06. CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. View filing ↗
- ANI Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. View filing ↗
- Standard BioTools Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Standard BioTools Inc.'s own proxy. As printed: 8,823,502. View filing ↗
- CareDx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
- Emergent BioSolutions Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. View filing ↗
- Quanterix Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. View filing ↗
- Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- Avid Bioservices (subject), Section 10b CEO total. DEF 14A, filed 2024-08-28. CEO total compensation as printed in Avid Bioservices's own proxy. As printed: 4,475,343. View filing ↗
- Pacific Biosciences of California, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. View filing ↗
- Codexis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. View filing ↗
- Lifecore Biomedical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Lifecore Biomedical, Inc.'s own proxy. As printed: 1,115,305. View filing ↗
- Harvard Bioscience, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Harvard Bioscience, Inc.'s own proxy. As printed: 905,208. View filing ↗